Latest Articles
Proteomics International Secures $4.5M for Promarker Test Launch - TipRanks
Proteomics International Secures $4.5M for Promarker Test Launch TipRanks
Published: April 22, 2025, 2:28 a.m.
Early voting begins today. Here's a cheat sheet of what Australians are being promised - SBS Australia
Early voting begins today. Here's a cheat sheet of what Australians are being promised SBS Australia
Published: April 21, 2025, 7:41 p.m.
Billions pledged: What the parties are promising for your health this election - SBS Australia
Billions pledged: What the parties are promising for your health this election SBS Australia
Published: April 12, 2025, 5:56 a.m.
Oroxylin A may promote cell apoptosis and inhibit epithelial-mesenchymal transition in endometrial cancer, associated with the ERβ/PI3K/AKT pathway - Nature
Oroxylin A may promote cell apoptosis and inhibit epithelial-mesenchymal transition in endometrial cancer, associated with the ERβ/PI3K/AKT pathway Nature
Published: April 10, 2025, 6:55 a.m.
Buy Rating Reaffirmed for Acrivon Therapeutics Amid Promising Endometrial Cancer Data and Strong Financial Position - TipRanks
Buy Rating Reaffirmed for Acrivon Therapeutics Amid Promising Endometrial Cancer Data and Strong Financial Position TipRanks
Published: April 1, 2025, 6:54 p.m.
Federal Labor promises half a billion dollars for women's health, including better access to long-term contraceptives - MSN
Federal Labor promises half a billion dollars for women's health, including better access to long-term contraceptives MSN
Published: March 29, 2025, 3:47 a.m.
Human-Specific Model of Endometriosis Shows Promise for Personalized Treatments - Physicians Committee for Responsible Medicine
Human-Specific Model of Endometriosis Shows Promise for Personalized Treatments Physicians Committee for Responsible Medicine
Published: March 28, 2025, 9:47 p.m.
Promising Phase 2 Results for ACR-368 in Endometrial Cancer Justify Buy Rating - TipRanks
Promising Phase 2 Results for ACR-368 in Endometrial Cancer Justify Buy Rating TipRanks
Published: March 26, 2025, 10:20 a.m.
Add-on metformin promising in ER-positive endometrial cancer - University of Cincinnati
Add-on metformin promising in ER-positive endometrial cancer University of Cincinnati
Published: March 24, 2025, 5:05 p.m.
Exosomal miR-92a-3p serves as a promising marker and potential therapeutic target for adenomyosis - Nature.com
Exosomal miR-92a-3p serves as a promising marker and potential therapeutic target for adenomyosis Nature.com
Published: March 22, 2025, 10:22 a.m.
Link copied to clipboard!